Geron Corporation or Taro Pharmaceutical Industries Ltd.: Who Leads in Yearly Revenue?

Taro's Revenue Dominance Over Geron: A Decade in Review

__timestampGeron CorporationTaro Pharmaceutical Industries Ltd.
Wednesday, January 1, 20141153000759285000
Thursday, January 1, 201536371000862944000
Friday, January 1, 20166162000950751000
Sunday, January 1, 20171065000879387000
Monday, January 1, 20181066000661913000
Tuesday, January 1, 2019460000669893000
Wednesday, January 1, 2020253000644769000
Friday, January 1, 20211393000548970000
Saturday, January 1, 2022596000561347000
Sunday, January 1, 2023237000572952000
Monday, January 1, 2024629182000
Loading chart...

Data in motion

A Tale of Two Companies: Geron vs. Taro

In the competitive landscape of pharmaceuticals, revenue is a key indicator of success. Over the past decade, Taro Pharmaceutical Industries Ltd. has consistently outperformed Geron Corporation in annual revenue. From 2014 to 2023, Taro's revenue has remained robust, peaking at approximately $950 million in 2016, while Geron's highest revenue was a modest $36 million in 2015. This stark contrast highlights Taro's dominance, with its revenue being over 100 times greater than Geron's in most years.

Despite Geron's innovative strides in biotechnology, its financial performance lags behind. Taro's steady revenue, even amidst global economic fluctuations, underscores its resilience and market leadership. As we look to the future, the missing data for 2024 leaves room for speculation. Will Geron close the gap, or will Taro continue to lead the charge? Only time will tell.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025